Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs – something Roche (ROG.S) aims to leverage, for example, with last month’s $2 billion purchase of Flatiron Health.
{iframe}https://www.reuters.com/article/us-pharmaceuticals-data/big-pharma-big-data-why-drugmakers-want-your-health-records-idUSKCN1GD4MM{/iframe}